Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...

Please provide your email address to receive an email when new articles are posted on . AvaGen, the Genetic Eye Test, can be performed in the eye care practice, helping doctors help their patients ...

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

In a new study, researchers at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs' ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, ...

Because the condition was bilateral, a corneal dystrophy was suspected. Lattice dystrophy typically presents with branching refractile lattice lines with intervening haze, which are observed best ...

The molecular changes that lead to Fuchs' endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research by UT ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

DUBLIN--(BUSINESS WIRE)--The "Fuchs Endothelial Corneal Dystrophy Market - A Global and Regional Analysis: Focus on Treatment Method, End User, and Region - Analysis and Forecast, 2025-2035" report ...